133 related articles for article (PubMed ID: 8278434)
21. Cannabinoid receptor binding and mRNA levels in several brain regions of adult male and female rats perinatally exposed to delta9-tetrahydrocannabinol.
García-Gil L; Romero J; Ramos JA; Fernández-Ruiz JJ
Drug Alcohol Depend; 1999 Jun; 55(1-2):127-36. PubMed ID: 10402157
[TBL] [Abstract][Full Text] [Related]
22. Lack of hippocampal CB1 receptor desensitization by Δ(9)-tetrahydrocannabinol in aged mice and by low doses of JZL 184.
Feliszek M; Bindila L; Lutz B; Zimmer A; Bilkei-Gorzo A; Schlicker E
Naunyn Schmiedebergs Arch Pharmacol; 2016 Jun; 389(6):603-12. PubMed ID: 26984820
[TBL] [Abstract][Full Text] [Related]
23. Identification of endocannabinoids and cannabinoid CB(1) receptor mRNA in the pituitary gland.
González S; Manzanares J; Berrendero F; Wenger T; Corchero J; Bisogno T; Romero J; Fuentes JA; Di Marzo V; Ramos JA; Fernández-Ruiz J
Neuroendocrinology; 1999 Aug; 70(2):137-45. PubMed ID: 10461028
[TBL] [Abstract][Full Text] [Related]
24. Pharmacological evaluation of dimethylheptyl analogs of delta 9-THC: reassessment of the putative three-point cannabinoid-receptor interaction.
Martin BR; Compton DR; Prescott WR; Barrett RL; Razdan RK
Drug Alcohol Depend; 1995 Mar; 37(3):231-40. PubMed ID: 7796717
[TBL] [Abstract][Full Text] [Related]
25. Opioid and cannabinoid modulation of precipitated withdrawal in delta(9)-tetrahydrocannabinol and morphine-dependent mice.
Lichtman AH; Sheikh SM; Loh HH; Martin BR
J Pharmacol Exp Ther; 2001 Sep; 298(3):1007-14. PubMed ID: 11504797
[TBL] [Abstract][Full Text] [Related]
26. Ras/ERK signalling in cannabinoid tolerance: from behaviour to cellular aspects.
Rubino T; Forlani G; Viganò D; Zippel R; Parolaro D
J Neurochem; 2005 May; 93(4):984-91. PubMed ID: 15857401
[TBL] [Abstract][Full Text] [Related]
27. Long-term cognitive deficits induced by a single, extremely low dose of tetrahydrocannabinol (THC): behavioral, pharmacological and biochemical studies in mice.
Senn R; Keren O; Hefetz A; Sarne Y
Pharmacol Biochem Behav; 2008 Jan; 88(3):230-7. PubMed ID: 17888506
[TBL] [Abstract][Full Text] [Related]
28. Cannabinoid receptor binding and messenger RNA expression in human brain: an in vitro receptor autoradiography and in situ hybridization histochemistry study of normal aged and Alzheimer's brains.
Westlake TM; Howlett AC; Bonner TI; Matsuda LA; Herkenham M
Neuroscience; 1994 Dec; 63(3):637-52. PubMed ID: 7898667
[TBL] [Abstract][Full Text] [Related]
29. Stereochemical effects of 11-OH-delta 8-tetrahydrocannabinol-dimethylheptyl to inhibit adenylate cyclase and bind to the cannabinoid receptor.
Howlett AC; Champion TM; Wilken GH; Mechoulam R
Neuropharmacology; 1990 Feb; 29(2):161-5. PubMed ID: 2158635
[TBL] [Abstract][Full Text] [Related]
30. Dose-dependent effects of Delta9-tetrahydrocannabinol on rates of local cerebral glucose utilization in rat.
Freedland CS; Whitlow CT; Miller MD; Porrino LJ
Synapse; 2002 Aug; 45(2):134-42. PubMed ID: 12112406
[TBL] [Abstract][Full Text] [Related]
31. Changes in opioid and cannabinoid receptor protein following short-term combination treatment with delta(9)-tetrahydrocannabinol and morphine.
Cichewicz DL; Haller VL; Welch SP
J Pharmacol Exp Ther; 2001 Apr; 297(1):121-7. PubMed ID: 11259535
[TBL] [Abstract][Full Text] [Related]
32. Cannabinoid CB(1) receptors colocalize with tyrosine hydroxylase in cultured fetal mesencephalic neurons and their activation increases the levels of this enzyme.
Hernández M; Berrendero F; Suárez I; García-Gil L; Cebeira M; Mackie K; Ramos JA; Fernández-Ruiz J
Brain Res; 2000 Feb; 857(1-2):56-65. PubMed ID: 10700552
[TBL] [Abstract][Full Text] [Related]
33. Competitive inhibition of delta8-tetrahydrocannabinol and its active metabolites for cannabinoid receptor binding.
Yamamoto I; Kimura T; Kamei A; Yoshida H; Watanabe K; Ho IK; Yoshimura H
Biol Pharm Bull; 1998 Apr; 21(4):408-10. PubMed ID: 9586583
[TBL] [Abstract][Full Text] [Related]
34. Chronic CP-55,940 alters cannabinoid receptor mRNA in the rat brain: an in situ hybridization study.
Rubino T; Massi P; Patrini G; Venier I; Giagnoni G; Parolaro D
Neuroreport; 1994 Dec; 5(18):2493-6. PubMed ID: 7696588
[TBL] [Abstract][Full Text] [Related]
35. Anandamides: tolerance and cross-tolerance to delta 9-tetrahydrocannabinol.
Fride E
Brain Res; 1995 Oct; 697(1-2):83-90. PubMed ID: 8593598
[TBL] [Abstract][Full Text] [Related]
36. Time-course of the effects of chronic delta 9-tetrahydrocannabinol on behaviour, body temperature, brain amines and withdrawal-like behaviour in the rat.
Taylor DA; Fennessy MR
J Pharm Pharmacol; 1982 Apr; 34(4):240-5. PubMed ID: 6124598
[TBL] [Abstract][Full Text] [Related]
37. Pharmacological evaluation of iodo and nitro analogs of delta 8-THC and delta 9-THC.
Martin BR; Compton DR; Semus SF; Lin S; Marciniak G; Grzybowska J; Charalambous A; Makriyannis A
Pharmacol Biochem Behav; 1993 Oct; 46(2):295-301. PubMed ID: 8265683
[TBL] [Abstract][Full Text] [Related]
38. Effect of (-)-Delta(9)-tetrahydrocannabinoid on the hepatic redox state of mice.
Pinto CE; Moura E; Serrão MP; Martins MJ; Vieira-Coelho MA
Braz J Med Biol Res; 2010 Apr; 43(4):325-9. PubMed ID: 20445947
[TBL] [Abstract][Full Text] [Related]
39. Delta-9-tetrahydrocannabinol differentially suppresses cisplatin-induced emesis and indices of motor function via cannabinoid CB(1) receptors in the least shrew.
Darmani NA
Pharmacol Biochem Behav; 2001; 69(1-2):239-49. PubMed ID: 11420092
[TBL] [Abstract][Full Text] [Related]
40. Effects of chronic administration of delta 9-tetrahydrocannabinol on the cardiovascular system, and pressor and behavioral responses to brain stimulation in freely moving rats.
Kawasaki H; Watanabe S; Ueki S
Eur J Pharmacol; 1980 Jul; 65(1):63-9. PubMed ID: 6249621
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
